AN OPEN-LABEL, MULTICENTRE, PHASE 1B/2 STUDY OF SAFETY AND EFFICACY OF KRT-232 COMBINED WITH A TYROSINE KINASE INHIBITOR (TKI) IN PATIENTS WITH RELAPSED OR REFRACTORY PH+ CHRONIC MYELOID LEUKEMIA (CML)

Registry ID

KRT-232-117

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

KARTOS THERAPEUTICS INC

Start date

2021-08-04

Last update

2021-03-08

Conditions

• CHRONIC MYELOID LEUKEMIA

Related clinical trials

• A PHASE 1A/1B STUDY OF ELVN-001 FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
• A PHASE IB STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
• A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES (OPTIC)
• A PHASE 1B DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY FOR THE COMBINATION OF DASATINIB (BMS-354825) PLUS NIVOLUMAB (BMS-936558) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
• A MULTI-CENTER, OPEN LABEL, NON-CONTROLLED PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL NILOTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN CHRONIC PHASE (CP) OR WITH PH+ CML IN CP OR ACCELERATED PHASE (AP) RESISTANT OR INTOLERANT TO EITHER IMATINIB OR DASATINIB

View on source registry